Urology Medical News about prostate cancer, sodium clodronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
The Lancet Oncology - Online First, 08/13/09

Dearnaley DP et al. - In a trial to assess the use of sodium clodronate in men with prostate cancer (PCa), it was shown that sodium clodronate improves overall survival (OS) in men with metastatic PCa who are starting hormone therapy, but there is no evidence of an effect in men with non-metastatic PCa.

Methods

311 men with metastatic disease were recruited to PR05 between 1994 and 1998, and 508 men with non-metastatic disease were recruited to PR04 from 1994 to 1997.
All men were treated according to the recruiting site's standard practice at the time: for metastatic disease, all men were starting or responding to long-term hormone therapy; for non-metastatic disease, most men had radiotherapy, hormone therapy, or both.
Men were randomly assigned to take 4 tablets per day of sodium clodronate (2080 mg) or matching placebo for up to 3 yrs (metastatic disease) or 5 yrs (non-metastatic).
Long-term OS was assessed on an intention-to-treat basis in all men using data from the National Health Service Information Centre, which held data for 278 of 311 men in the PR05 trial and 471 of 508 men in the PR04 trial.

Results

Of the 278 men with metastatic disease, 258 (93%) were reported to have died.
Evidence of a benefit for those with metastatic disease from use of sodium clodronate compared with placebo was seen in OS.
Of the 471 men with non-metastatic disease, 281 (60%) were reported to have died, with no evidence of improvement in OS with clodronate compared with placebo.

<< Previous
Survivin Expression as a Predictive Marker for Local Control in...

Next >>
Intraoperative Photodynamic Evaluation of Surgical Margins During...